Philip A. Pizzo, M.D.

Publication Details

  • Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection Sei, S., Sandelli, S. L., Theofan, G., Ratto-Kim, S., Kumagai, M., Loomis-Price, L. D., Cox, J. H., Jarosinski, P., Walsek, C. M., Brouwers, P., VENZON, D. J., Xu, J., Pizzo, P. A., Moss, R. B., ROBB, M. L., Wood, L. V. UNIV CHICAGO PRESS. 1999: 626-640


    The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2. 5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log10 HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n=4] vs. 2.5 U [n=3], respectively; P=.034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P<.02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P<.01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.

    View details for Web of Science ID 000082246300009

    View details for PubMedID 10438349

Stanford Medicine Resources:

Footer Links: